🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Suzhou Zelgen Biopharmaceuticals clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with Suzhou Zelgen Biopharmaceuticals as lead sponsor. Synced 26 Sep 2026
23Current trials
15Recruiting now
12Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Suzhou Zelgen Biopharmaceuticals is the lead sponsor of 23 current clinical trials in our China and USA registers. 15 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are ZG006, ZG005 and Bevacizumab. The most-studied condition is Small Cell Lung Cancer.

ClinicalTrials.gov trials by status

  • Recruiting1565%
  • Not yet open417%
  • Active, closed417%

Trials by phase

  • Phase 1/21148%
  • Phase 3522%
  • Phase 2417%
  • Phase 1313%
01

Clinical trials sponsored by Suzhou Zelgen Biopharmaceuticals

23 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
NCT06558227 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Phase 2 Recruiting 2024-10 China
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
NCT07231445 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer
Phase 1 Recruiting 2026-04 China
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
NCT06903377 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer
Phase 1/2 Recruiting 2025-05 China
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
NCT05978284 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Neuroendocrine Carcinoma
Drug: ZG006
Phase 1/2 Recruiting 2023-10 China
Study of ZGGS18 in Patients With Advanced Solid Tumors
NCT05584800 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Drug: ZGGS18
Phase 1/2 Recruiting 2022-11 China
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
NCT06283719 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Neuroendocrine Cancer
Drug: ZG006
Phase 1/2 Recruiting 2024-09 China
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
NCT07189455 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer
Phase 3 Recruiting 2025-12 China
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
NCT06592638 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer
Drug: ZG006
Phase 1 Recruiting 2025-03 USA
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
NCT06440057 · ClinicalTrials.gov ↗ · Neuroendocrine Carcinoma
Drug: ZG006
Phase 1/2 Recruiting 2024-08 China
Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma
NCT07099547 · ClinicalTrials.gov ↗ · Biliary Tract Carcinoma
Phase 2 Recruiting 2025-12 China
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
NCT07080216 · ClinicalTrials.gov ↗ · Cervical Cancer
Phase 1/2 Recruiting 2025-09 China
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
NCT06883526 · ClinicalTrials.gov ↗ · Lymphoma
Phase 1/2 Recruiting 2025-05 China
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
NCT07038096 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Neuroendocrine Carcinoma
Drugs: ZG005, ZG006
Phase 1/2 Recruiting 2025-09 China
Study of ZGGS34 in Participants With Advanced Solid Tumors
NCT07258121 · ClinicalTrials.gov ↗ · Solid Tumor
Drug: ZG006
Phase 1/2 Recruiting 2025-12 China
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
NCT06938880 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Drugs: ZG005, ZGGS18
Phase 1/2 Recruiting 2025-05 China
Study of ZG006 in Participants With Neuroendocrine Prostate Cancer
NCT07024277 · ClinicalTrials.gov ↗ · Neuroendocrine Prostate Cancer
Drug: ZG006
Phase 2 Not yet open 2025-08 China
A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
NCT07595913 · ClinicalTrials.gov ↗ · Neuroendocrine Carcinoma
Drug: ZG006
Phase 3 Not yet open 2026-07 China
Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors
NCT07142837 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1/2 Not yet open 2025-09 China
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
NCT07813572 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Phase 3 Not yet open 2026-09 China
A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.
NCT07565597 · ClinicalTrials.gov ↗ · Healthy
Phase 1 Active, closed 2026-05 China
A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis
NCT05526222 · ClinicalTrials.gov ↗ · Atopic Dermatitis
Phase 3 Active, closed 2022-07 China
Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)
NCT05861102 · ClinicalTrials.gov ↗ · Ankylosing Spondylitis
Phase 3 Active, closed 2023-07 China
Study of ZG005 in Patients With Advanced Solid Tumors
NCT06927687 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Drug: ZG005
Phase 2 Active, closed 2025-06 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Suzhou Zelgen Biopharmaceuticals trials

12 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Suzhou Zelgen Biopharmaceuticals trials

15 conditions
Small Cell Lung Cancer5Neuroendocrine Carcinoma4Advanced Solid Tumor4Hepatocellular Carcinoma2Non-small Cell Lung Cancer1Healthy1Neuroendocrine Cancer1Small-cell Lung Cancer1Atopic Dermatitis1Ankylosing Spondylitis1Biliary Tract Carcinoma1Cervical Cancer1Lymphoma1Neuroendocrine Prostate Cancer1Solid Tumor1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2214
Clinical trials in USA11

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Small Cell Lung Cancer

SponsorTrials
Amgen4
China Medical University, China2
Hangzhou DAC Biotechnology2
Nerviano Medical Sciences1
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair1
Yunpeng Liu1
Heronova Pharmaceuticals1
Tianjin First Central Hospital1

Sponsors with the most current trials registered for this condition.

06

Questions about Suzhou Zelgen Biopharmaceuticals trials

How many clinical trials does Suzhou Zelgen Biopharmaceuticals sponsor?

Suzhou Zelgen Biopharmaceuticals is the lead sponsor of 23 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Suzhou Zelgen Biopharmaceuticals trials recruiting?

Yes. 15 of its 23 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Suzhou Zelgen Biopharmaceuticals testing?

Its current trials name 12 drugs and biologicals as interventions. The most frequent are ZG006 (10), ZG005 (9), Bevacizumab (3), Gecacitinib (2) and Gecacitinib Hydrochloride (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.